Global Tacrolimus Capsules Market Insights and Forecast to 2028

It is used to keep the body from harming the organ after an organ transplant. 
Market Analysis and Insights: Global Tacrolimus Capsules Market
Due to the COVID-19 pandemic, the global Tacrolimus Capsules market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 0.5mg/pill accounting for % of the Tacrolimus Capsules global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Tacrolimus Capsules market size is valued at US$ million in 2021, while the US and Europe Tacrolimus Capsules are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Tacrolimus Capsules landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Tacrolimus Capsules include Accord Healthcare, Bionpharma, Major Pharmaceuticals, Sandoz, Astellas Pharma, Lannett, Mylan, Hisun Pharm and Zhejiang Hongsheng Pharm and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Tacrolimus Capsules Scope and Segment
Tacrolimus Capsules market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Tacrolimus Capsules market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
0.5mg/pill
1mg/pill
5mg/pill
Segment by Application
Hospital
Special Clinic
Recovery Center
By Company
Accord Healthcare
Bionpharma
Major Pharmaceuticals
Sandoz
Astellas Pharma
Lannett
Mylan
Hisun Pharm
Zhejiang Hongsheng Pharm
Huadong Medicine
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Frequently Asked Questions